Ctrl K
Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -55.84 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 26.55 | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +376.4% | — | — | |
| P/B Ratio | 21.48 | 20.28 | 6.79 | 8.14 | 3.82 | 8.25 | 3.41 | 8.13 | 5.37 | 23.54 | 4.67 | — | — | 9.19 | 2.56 | 10.11 | 3.30 | 2.37 | 26.38 | 4.32 | 5.46 |
| — | +145.7% | +98.9% | +0.2% | -28.8% | -64.9% | -26.9% | — | — | +156.2% | +82.8% | — | — | +287.1% | -90.3% | +134.1% | -39.7% | -53.2% | +496.9% | +100.2% | +94.7% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 85.5% | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -13.0% | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -673.5% | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1610.0% | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -1674.4% | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -3871.7% | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -66.9% | -7.8% | -9.4% | -13.1% | -18.9% | -24.5% | -31.2% | -53.1% | -75.6% | -118.6% | -1120.1% | — | -1824.2% | -98.2% | -123.2% | -104.6% | -44.4% | -72.9% | -137.4% | -28.1% | -23.6% |
| — | +68.0% | +69.8% | +75.3% | +75.0% | +79.4% | +97.2% | — | +95.9% | -20.8% | -809.5% | — | -4011.6% | -34.6% | +10.4% | -272.0% | -87.9% | -391.2% | -1521.1% | -35.8% | +69.0% | |
| ROA | -54.9% | -7.4% | -8.7% | -11.8% | -16.2% | -19.6% | -21.4% | -29.3% | -34.2% | -37.8% | -62.4% | -113.8% | -69.5% | -37.1% | -44.3% | -38.9% | -24.1% | -31.4% | -70.0% | -20.5% | -17.4% |
| — | +62.3% | +59.1% | +59.8% | +52.6% | +48.0% | +65.8% | +74.2% | +50.9% | -1.8% | -40.7% | -192.7% | -188.2% | -18.2% | +36.6% | -89.6% | -38.9% | -186.3% | -1161.1% | -78.1% | +35.9% | |
| ROIC | — | -1538.9% | -1303.1% | -692.5% | -312.7% | -566.1% | — | — | — | — | — | — | — | — | — | — | — | — | — | -1005.5% | -187.4% |
| — | -171.8% | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | +38.7% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.03 | 0.03 | 0.11 | 0.04 | 0.24 | 0.08 | — | — | 0.15 | 0.06 | 0.19 | 0.08 | 0.06 | 0.30 | 0.04 | 0.03 |
| — | -81.0% | -74.1% | -86.6% | -63.8% | -88.1% | -62.1% | — | — | +53.6% | +28.3% | — | — | +162.2% | -78.5% | +390.6% | +155.3% | +118.3% | +809.0% | +12.0% | -74.6% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 10.72 | 18.83 | 17.22 | 10.72 | 8.28 | 4.91 | 4.64 | 1.72 | 2.26 | 1.02 | 1.49 | 0.23 | 0.44 | 1.16 | 1.68 | 1.14 | 1.80 | 2.36 | 1.67 | 4.63 | 5.45 |
| — | +283.6% | +271.0% | +524.3% | +265.6% | +380.6% | +211.7% | +643.4% | +410.8% | -12.0% | -11.2% | -79.8% | -75.4% | -50.8% | +0.4% | -75.3% | -66.9% | -71.1% | -68.3% | +54.5% | +146.2% | |
| Quick Ratio | 10.72 | 18.83 | 17.22 | 10.72 | 8.28 | 4.91 | 4.64 | 1.72 | 2.26 | 1.02 | 1.49 | 0.23 | 0.44 | 1.16 | 1.68 | 1.14 | 1.80 | 2.36 | 1.67 | 4.63 | 5.45 |
| — | +283.6% | +271.0% | +524.3% | +265.6% | +380.6% | +211.7% | +643.4% | +410.8% | -12.0% | -11.2% | -79.8% | -75.4% | -50.8% | +0.4% | -75.3% | -66.9% | -71.1% | -68.3% | +54.5% | +146.2% | |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLS stock.
SELLAS Life Sciences Group, Inc.'s current P/E is -55.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking SELLAS Life Sciences Group, Inc.'s business trajectory between earnings reports.